Sage Therapeutics Inc. Stock
Price
Target price
€12.78
€12.78
-0.350%
-0.045
-0.350%
€43.36
26.04.24 / Tradegate
WKN: A117WF / Symbol: SAGE / Name: SAGE / Stock / Biotechnology & Medical Research / Mid Cap /
Please give a prediction to see the opinions of the community
sharewise uses Wisdom of crowds to gather information regarding a security. Wisdom of crowds works best if you do not see the predictions of others before giving your estimate. Please click one button to see how the community sees this security.
Your prediction
Sage Therapeutics Inc. Stock
The price for the Sage Therapeutics Inc. stock decreased slightly today. Compared to yesterday there is a change of -€0.045 (-0.350%).
With 4 Buy predictions and 3 Sell predictions the community is currently undecided on Sage Therapeutics Inc..
With a target price of 43 € there is potential for a 236.59% increase which would mean more than doubling the current price of 12.78 € for Sage Therapeutics Inc..
So far the community has only identified positive things for Sage Therapeutics Inc. stock. The most positive votes were given for criterium "Valuation (undervalued/overvalued)".
Pros and Cons of Sage Therapeutics Inc. in the next few years
Pros
?
C******** o* t** e**********
?
G***** c******* t* c**********
?
B****
Cons
?
W********* I********* f** t** n*** y****
?
M***** P*******
?
S********** s********
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Sage Therapeutics Inc. vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Sage Therapeutics Inc. | -0.350% | 2.037% | -26.156% | -70.428% | -36.125% | -80.292% | - |
| Iovance Biotherapeutics Inc. | -1.440% | 2.211% | -16.359% | 119.362% | 39.152% | -60.289% | - |
| Novocure Ltd | 3.070% | 4.053% | -2.114% | -79.652% | -17.268% | -93.443% | - |
| Fibrogen Inc. | -0.330% | -11.959% | -58.142% | -94.914% | 10.000% | -94.708% | - |
Comments
Sage Therapeutics, Inc. (NASDAQ: SAGE) was downgraded by analysts at StockNews.com from a "hold" rating to a "sell" rating.
Show more
Ratings data for SAGE provided by MarketBeat
Sage Therapeutics, Inc. (NASDAQ: SAGE) had its price target raised by analysts at JPMorgan Chase & Co. from $24.00 to $29.00. They now have an "overweight" rating on the stock.
Show more
Ratings data for SAGE provided by MarketBeat
Sage Therapeutics, Inc. (NASDAQ: SAGE) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.
Show more
Ratings data for SAGE provided by MarketBeat
News
5 Biotech stocks tapping into unmet mental health treatment needs
Anyone who has dealt with a mental illness or has a loved one who struggles with a mental illness knows how devastating these diseases are. However, a growing number of biotechnology companies are
Why Sage Therapeutics Stock Sank Today
It wasn't a wise move for investors to hold or buy Sage Therapeutics (NASDAQ: SAGE) shares on Tuesday. Its price tumbled by nearly 5% as the market digested the healthcare company's third-quarter
